 |
|
|
| |
Cilofexor and Firsocostat in Combination Lead to Greater Reductions in Serum Bile Acids, Which Are Associated With Treatment Response in Patients With Advanced Fibrosis Due to NASH
|
| |
| |
AASLD 2020 Nov 11-16
Rohit Loomba,1 Mazen Noureddin,2 Kris V. Kowdley,3 Anita Kohli,4 Aasim Sheikh,5 Bal Raj Bhandari,6 Jen-Chieh Chuang,7 Andrew Billin,7 Scott D. Patterson,7 Lulu Wang,7 Catherine Jia,7 Ryan S. Huss,7 Robert P. Myers,7 Keyur Patel,8 Heidi Kabler,9 Peter Ruane,10 Simone Strasser,11 Vincent Wai-Sun Wong,12 Naim Alkhouri13
1UC San Diego NAFLD Research Center, La Jolla, CA; 2Cedars-Sinai Fatty Liver Program, Los Angeles, CA; 3Liver Institute Northwest and Washington State University, Seattle, WA; 4Arizona Liver Health, Chandler, AZ; 5GI Specialists of Georgia, Marietta; 6Delta Research Partners, LLC, Bastrop, LA; 7Gilead Sciences, Inc., Foster City, CA; 8Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; 9MountainView Hospital, Las Vegas, NV; 10Ruane Medical & Liver Health Institute, Los Angeles; 11Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; 12The Chinese University of Hong Kong, People's Republic of China; 13Texas Liver Institute, UT Health San Antonio, TX
References: 1. Sanyal AJ, et al. EASL 2018, poster FRI-422; 2. Loomba R, et al. EASL 2020, abstr LBO04. 3. Harrison S, et al. AASLD 2017, poster 2122.
|
| |
|
|
|
|
|
